Barclays PLC boosted its stake in Veru Inc. (NASDAQ:VERU – Free Report) by 309.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 184,777 shares of the company’s stock after buying an additional 139,617 shares during the period. Barclays PLC owned approximately 0.13% of Veru worth $142,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Gladstone Institutional Advisory LLC boosted its position in Veru by 34.2% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock worth $44,000 after buying an additional 14,500 shares during the period. Blair William & Co. IL increased its stake in shares of Veru by 6.1% in the second quarter. Blair William & Co. IL now owns 350,000 shares of the company’s stock valued at $294,000 after buying an additional 20,000 shares during the period. Zacks Investment Management bought a new position in shares of Veru during the third quarter worth about $25,000. SG Americas Securities LLC boosted its holdings in Veru by 185.9% in the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock valued at $51,000 after acquiring an additional 42,997 shares during the last quarter. Finally, Jane Street Group LLC increased its position in Veru by 142.8% during the 3rd quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock valued at $74,000 after purchasing an additional 56,736 shares during the period. 47.16% of the stock is owned by institutional investors.
Veru Price Performance
Shares of NASDAQ VERU opened at $0.74 on Wednesday. The company has a 50-day moving average price of $0.69 and a 200-day moving average price of $0.80. The stock has a market capitalization of $108.95 million, a P/E ratio of -1.55 and a beta of -0.53. Veru Inc. has a 1 year low of $0.36 and a 1 year high of $1.92.
Wall Street Analyst Weigh In
VERU has been the subject of several recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $5.00 target price on shares of Veru in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Veru in a research note on Thursday, January 2nd.
Get Our Latest Stock Analysis on VERU
Veru Profile
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
- Five stocks we like better than Veru
- 3 Small Caps With Big Return Potential
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- With Risk Tolerance, One Size Does Not Fit All
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- How to Invest in Small Cap Stocks
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.